Morning Briefing
Summaries of health policy coverage from major news organizations
Theranos' Fate Could Hinge On Thin Line Between Rosy Projections And False Promotion
At worst, if investigators find evidence of hype that crosses the line with the blood-testing startup, its executives could face jail time. Meanwhile, Theranos board member David Boies says he has confidence in CEO Elizabeth Holmes following news of investigations into the company.
When does hype cross the line into illegal activity? That鈥檚 the big question animating criminal and civil probes into Theranos, the once high-flying Silicon Valley startup that aimed to revolutionize medical testing by developing technology that could perform an array of lab tests with just a few drops of blood. (Robbins, 4/19)
Theranos Inc. board member David Boies defended Chief Executive Officer Elizabeth Holmes on Tuesday, saying she has the management and scientific skills to lead the blood-testing startup despite criminal and civil investigations of the company by U.S. authorities. (Kohlatkar and Chen, 4/19)
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
